Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
First presentation of health-related quality of life results for Dupixent in children aged 6 to 11 years with uncontrolled asthma, as well as analyses on the impact of Dupixent on physical activity limitation and sleep in adolescents and adults with OCS-dependent asthma.
Lead Product(s): Dupilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2021